Initially, IBM Watson Health’s Imaging group will distribute the MedyMatch brain bleed detection application globally through its vendor neutral sales channels.
Moving forward, IBM Watson Health and MedyMatch will develop interoperability between MedyMatch’s application and IBM Watson Health Imaging’s offerings.
According to the American Heart Association and American Stroke Association (AHA/ASA), stroke is the fourth leading cause of death and one of the top causes of preventable disability in the United States.
Affecting 4% of the U.S. adults, it is forecasted that by 2030, there will be approximately 3.4 million stroke victims annually in the U.S., costing the healthcare system $240bn on an annual basis.
MedyMatch aims to bring cognitive tools into the daily workflow of an emergency department to help physicians assess patients suspected of head trauma or stroke, and rule out the presence of a bleed in the brain.
The MedyMatch algorithm uses sophisticated deep learning, machine vision, patient data, and clinical insights to automatically highlight for a physician regions of interest that could indicate the potential presence of cerebral bleeds –and does so without interrupting how a physician works.
MedyMatch chairman and CEO Gene Saragnese said: “The opportunity to license our deep vision application to IBM Watson Health creates a unique value proposition in healthcare.
“Engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering ‘A.I. to the bedside’ where I believe the future of healthcare lies. At MedyMatch, we believe improvements in the interpretation of data will lead to better decisions, better decisions will lead to better outcomes for patients and lower cost for healthcare. This is what drives us forward every day.”
Massachusetts General Hospital emergency radiology director and Harvard Medical School radiology director Michael Lev said: “The implementation of A.I.-based computer aided detection and clinical decision support tools to medicine in general, and to the emergency department, in particular, has the potential to increase the speed, accuracy, and efficiency of patient management – with the potential to ultimately reduce diagnostic errors and improving clinical outcomes.
“MedyMatch is ideally positioned to leverage this technology, and their willingness to collaborate with industry partners reflects their awareness of, and sensitivity to, the complexities of patient assessment in the acute care setting. The Company’s first algorithms – CT detection of intracranial bleeds – represents the confluence of physician know-how and artificial intelligence clinical support.”
IBM Watson Health imaging vice president Anne Le Grand said: “The opportunity to leverage MedyMatch’s inventive technology is an exciting addition to the vendor-neutral capabilities we are working to deliver to providers who specialize in brain health.
“IBMs alliance with MedyMatch supports Watson Health’s global strategy to apply the power of Watson to the world’s most pressing healthcare challenges.
MedyMatch is currently conducting a clinical trial for its intracranial bleed assessment application and is working towards a PMA Class III approval by the U.S. FDA.
